The Effect of Bazedoxifene and Fulvestrant for Preventing Ovarian Hyperstimulation Syndrome: An Experimental Study

Fatma Özdemir; Gökhan Açmaz; Arzu Yay; Özge Cengiz Mat; Gözde Ertürk Zararsız; Banu Açmaz; İptisam İpek Müderris; Sabahattin Muhtaroğlu; Erol Karakaş; Mevlüde İnanç

doi:10.3390/jcm14207435

The Effect of Bazedoxifene and Fulvestrant for Preventing Ovarian Hyperstimulation Syndrome: An Experimental Study

Fatma Özdemir, Gökhan Açmaz, Arzu Yay, Özge Cengiz Mat, Gözde Ertürk Zararsız, Banu Açmaz, İptisam İpek Müderris, Sabahattin Muhtaroğlu, Erol Karakaş, Mevlüde İnanç

In: Journal of Clinical Medicine · 2025 · vol. 14(20) , pp. 7435 · doi:10.3390/jcm14207435 · PMID:41156301 · W4415401501

article OA: gold CC0

🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Fulvestrant and bazedoxifene showed potential in an experimental study to reduce ovarian hyperstimulation syndrome severity by decreasing ascites and weight gain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Fulvestrant and bazedoxifene may reduce OHSS severity by lowering ascites formation and weight gain. These agents could be potential therapeutic candidates for OHSS with appropriate timing and dosage.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Bazedoxifene–Conjugated Estrogens for Treating Endometriosis 2018

References (41)

Bazedoxifene–Conjugated Estrogens for Treating Endometriosis via openalex
doi:10.3906/sag-2005-297 via openalex
doi:10.3390/curroncol31100426 via openalex
doi:10.3390/cancers14040909 via openalex
doi:10.1002/vms3.936 via openalex
doi:10.1097/gme.0b013e3181a818db via openalex
doi:10.1007/s00404-020-05855-1 via openalex
doi:10.1530/rep-17-0268 via openalex
doi:10.1002/ijc.32043 via openalex
doi:10.1007/s10815-010-9387-6 via openalex
doi:10.1371/journal.pone.0060889 via openalex
doi:10.1186/1477-7827-1-75 via openalex
doi:10.1359/jbmr.080710 via openalex
doi:10.1089/jwh.2013.4392 via openalex
doi:10.3109/09513590.2015.1077218 via openalex
doi:10.1016/j.reprotox.2025.109033 via openalex
doi:10.1080/13697137.2021.1936485 via openalex
doi:10.1200/jco.2010.28.8415 via openalex
doi:10.1016/j.mehy.2007.11.004 via openalex
doi:10.1038/s12276-020-00491-w via openalex
doi:10.1186/s13048-020-00724-6 via openalex
doi:10.21873/invivo.12135 via openalex
doi:10.1200/jco.2008.21.1136 via openalex
doi:10.1016/j.etap.2022.103933 via openalex
doi:10.3390/ijms22168693 via openalex
doi:10.1186/s12906-025-05013-7 via openalex
doi:10.1016/s0140-6736(16)32389-3 via openalex
doi:10.1016/j.fertnstert.2010.03.028 via openalex
doi:10.1016/j.fertnstert.2016.08.048 via openalex
doi:10.1002/uog.14684 via openalex
doi:10.1016/j.ejca.2019.10.015 via openalex
doi:10.1210/en.2005-0030 via openalex
doi:10.14744/cpr.2025.94220 via openalex
doi:10.1002/cpdd.438 via openalex
doi:10.1016/j.cell.2019.06.026 via openalex
doi:10.1507/endocrj.50.515 via openalex
doi:10.2741/2339 via openalex
doi:10.1007/s10549-019-05454-y via openalex
doi:10.1080/01443615.2018.1563774 via openalex
doi:10.1007/s10815-013-0151-6 via openalex
doi:10.3816/cbc.2005.s.008 via openalex

Source provenance

openalex: last seen: 2026-05-14T06:20:05.154166+00:00

License: CC0 · commercial use OK

[1] Bazedoxifene–Conjugated Estrogens for Treating Endometriosis 2018